Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(5):336-337; doi:10.1093/jnci/97.5.336
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Webb, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Webb, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Vascular Normalization: Study Examines How Antiangiogenesis Therapies Work

Tracy Webb

The first 10% of the full text of this article appears below.

It is a widely held belief that antiangiogenic therapy eradicates tumor vasculature, thus depriving the tumor of oxygen and nutrients necessary for survival. But this may not be the complete story. A new study published in December in Cancer Cell suggests that antiangiogenic therapy may also "normalize" the tumor vasculature for a short period of time, thereby providing a window of opportunity for improved drug delivery and enhanced sensitivity to radiation treatment.

Clinical trials have suggested a benefit to giving antiangiogenic agents in combination with other . . . [Full Text of this Article]

Window of Normalization

Clinical Concerns


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?